ESSA Pharma to be Acquired by XenoTherapeutics

ESSA Pharma ( (EPIX) ) just unveiled an announcement.

On July 13, 2025, ESSA Pharma Inc. announced a definitive agreement to be acquired by XenoTherapeutics, Inc., a Massachusetts-based non-profit biotechnology company. The transaction, backed by XOMA Royalty Corporation, involves Xeno acquiring all outstanding common shares of ESSA. Shareholders will receive a cash payment per share based on ESSA’s cash balance at closing, along with a non-transferable contingent value right for potential additional payments. The transaction is structured to expedite cash distribution to shareholders and is expected to close in the second half of 2025, pending court and shareholder approvals. The ESSA Board of Directors has unanimously approved the transaction, deeming it in the best interest of the company as it plans to discontinue operations and wind down its business.

The most recent analyst rating on (EPIX) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on ESSA Pharma stock, see the EPIX Stock Forecast page.

Spark’s Take on EPIX Stock

According to Spark, TipRanks’ AI Analyst, EPIX is a Neutral.

ESSA Pharma’s overall score reflects significant financial challenges with no revenue and ongoing losses. Technical indicators provide some positive signals, but caution is advised due to potential overbought conditions. The negative P/E ratio and lack of dividends further underline investment risks.

To see Spark’s full report on EPIX stock, click here.

More about ESSA Pharma

ESSA Pharma Inc. is a pharmaceutical company that was previously focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer.

Average Trading Volume: 140,388

Technical Sentiment Signal: Sell

Current Market Cap: $75.9M

See more insights into EPIX stock on TipRanks’ Stock Analysis page.